MGMT and neoplasm: An important prognostic marker is the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT), and patients harboring the methylated (silenced) MGMT promoter have a better prognosis than patients with the tumor-unmethylated (active) MGMT promoter, with overall survival times of 12.2 and 18.2 months, respectively [2].